EFM
E Fund Management Portfolio holdings
AUM
$2.1B
1-Year Return
23.31%
This Quarter Return
-11.93%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$3.06B
AUM Growth
+$226M
(+8%)
Cap. Flow
+$578M
Cap. Flow
% of AUM
18.9%
Top 10 Holdings %
Top 10 Hldgs %
83.2%
Holding
374
New
73
Increased
133
Reduced
109
Closed
49
Top Buys
| 1 |
Alibaba
BABA
|
$315M |
| 2 |
Baidu
BIDU
|
$74M |
| 3 |
JD.com
JD
|
$72M |
| 4 |
NetEase
NTES
|
$47.9M |
| 5 |
Pinduoduo
PDD
|
$39.6M |
Top Sells
| 1 |
NIO
NIO
|
$10.7M |
| 2 |
KC
Kingsoft Cloud Holdings
KC
|
$9.2M |
| 3 |
SPDR S&P 500 ETF Trust
SPY
|
$7.55M |
| 4 |
Invesco QQQ Trust
QQQ
|
$7.48M |
| 5 |
United States Brent Oil Fund
BNO
|
$6.73M |
Sector Composition
| 1 | Consumer Discretionary | 63.45% |
| 2 | Communication Services | 21.89% |
| 3 | Technology | 6.77% |
| 4 | Healthcare | 2.13% |
| 5 | Financials | 1.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Corning
GLW
$61B
| $293K | 0.01% |
7,925
+444
| +6% | +$16.4K |
|
202
PTC Therapeutics
PTCT
$4.55B
| $292K | 0.01% |
+7,830
| New | +$292K |
|
203
Stryker
SYK
$150B
| $291K | 0.01% |
1,089
-123
| -10% | -$32.9K |
|
204
Exelixis
EXEL
$10.2B
| $290K | 0.01% |
12,780
+2,416
| +23% | +$54.8K |
|
205
TG Therapeutics
TGTX
$5.11B
| $290K | 0.01% |
30,483
+20,017
| +191% | +$190K |
|
206
Alkermes
ALKS
$4.94B
| $289K | 0.01% |
+11,003
| New | +$289K |
|
207
Ironwood Pharmaceuticals
IRWD
$188M
| $289K | 0.01% |
22,986
+7,384
| +47% | +$92.8K |
|
208
RTX Corp
RTX
$211B
| $289K | 0.01% |
2,920
-407
| -12% | -$40.3K |
|
209
Enphase Energy
ENPH
$5.18B
| $288K | 0.01% |
1,427
+112
| +9% | +$22.6K |
|
|
SRNE
210
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $287K | 0.01% |
123,048
+95,216
| +342% | +$222K |
|
|
SAGE
211
DELISTED
Sage Therapeutics
SAGE
| $286K | 0.01% |
+8,634
| New | +$286K |
|
212
Insmed
INSM
$30.7B
| $285K | 0.01% |
+12,116
| New | +$285K |
|
213
Philip Morris
PM
$251B
| $285K | 0.01% |
3,037
-402
| -12% | -$37.7K |
|
214
Denali Therapeutics
DNLI
$2.26B
| $284K | 0.01% |
+8,827
| New | +$284K |
|
215
Royal Caribbean
RCL
$95.7B
| $284K | 0.01% |
3,388
-39
| -1% | -$3.27K |
|
216
Zoetis
ZTS
$67.9B
| $284K | 0.01% |
1,504
-72
| -5% | -$13.6K |
|
|
CCXI
217
DELISTED
ChemoCentryx, Inc.
CCXI
| $284K | 0.01% |
+11,309
| New | +$284K |
|
218
Alnylam Pharmaceuticals
ALNY
$59.2B
| $283K | 0.01% |
+1,732
| New | +$283K |
|
219
S&P Global
SPGI
$164B
| $283K | 0.01% |
691
+162
| +31% | +$66.3K |
|
220
Neurocrine Biosciences
NBIX
$14.3B
| $282K | 0.01% |
+3,005
| New | +$282K |
|
221
Acadia Pharmaceuticals
ACAD
$4.26B
| $280K | 0.01% |
+11,573
| New | +$280K |
|
222
Natera
NTRA
$23.1B
| $280K | 0.01% |
+6,882
| New | +$280K |
|
223
Opko Health
OPK
$1.07B
| $280K | 0.01% |
81,338
+53,299
| +190% | +$183K |
|
224
Zentalis Pharmaceuticals
ZNTL
$126M
| $280K | 0.01% |
+6,079
| New | +$280K |
|
|
HZNP
225
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $280K | 0.01% |
+2,663
| New | +$280K |
|